Annex VII amendments under MDR and IVDR: What manufacturers should know
Key insights into the latest Annex VII amendments and their impact on MDR and IVDR certification
The recent amendments to Annex VII of the European Medical Device Regulation (MDR) and In Vitro Diagnostic Medical Device Regulation (IVDR) represent another important step in the continued evolution of the European regulatory framework.
While the amendments introduce measures intended to improve the operation of the conformity assessment system, they should not be interpreted as a relaxation of regulatory requirements. Manufacturers will still be expected to demonstrate compliance through robust technical documentation, effective quality management systems and strong regulatory processes.
Instead, the changes are designed to improve the consistency, transparency and predictability of conformity assessments, benefiting both manufacturers and Notified Bodies.
Supporting a more mature conformity assessment system
Since MDR and IVDR came into force, regulators, manufacturers and Notified Bodies have gained significant experience applying the new regulations in practice. The Annex VII amendments reflect this continued maturation of the regulatory system.
From DNV's perspective, the amendments are a positive development that supports:
- Greater consistency in how conformity assessments are performed across Notified Bodies
- Increased transparency throughout the certification process
- Improved predictability for manufacturers planning certification and recertification activities
- A more harmonized approach to conformity assessment across Europe
Importantly, these changes do not reduce expectations around safety, clinical or performance evidence, or regulatory compliance. The level of scrutiny required to demonstrate compliance remains unchanged.
What the amendments mean for manufacturers
For manufacturers, the greatest value of the amendments lies in improved planning certainty.
As implementation becomes more consistent, organisations can expect clearer visibility into assessment processes, timelines and regulatory expectations. This can help support more effective resource planning and reduce uncertainty throughout certification activities.
Potential benefits include:
- Greater transparency around assessment activities and expected timelines
- Increased consistency across different Notified Bodies
- More predictable planning for certification and recertification
- Clearer expectations for submissions and change notifications
However, these benefits are most likely to be realised by manufacturers that already have mature regulatory capabilities.
Organizations with well-established quality management systems, high-quality technical documentation, effective change management processes and robust regulatory planning will be best positioned to take advantage of the increased predictability offered by the amendments.
Submission quality remains critical
Although the amendments may streamline aspects of the conformity assessment process, they do not change the importance of submission quality.
Incomplete documentation, unclear evidence or poorly managed changes will continue to create delays regardless of procedural improvements.
Manufacturers should therefore continue to focus on four key areas:
- Preparing complete and high-quality submissions
- Planning certification and recertification activities well in advance
- Maintaining effective change management processes
- Ensuring ongoing regulatory readiness
These fundamentals remain the strongest contributors to an efficient conformity assessment process.
A shared commitment to predictable certification
The success of the Annex VII amendments depends on more than regulatory changes alone.
Achieving greater efficiency and predictability requires both manufacturers and Notified Bodies to work within agreed timelines, maintain open communication and provide complete, high-quality information throughout the certification journey.
As experience with MDR and IVDR continues to grow, these amendments represent another important step towards a more consistent and transparent European conformity assessment system, while maintaining the high standards of safety and performance expected under the regulations.
7/13/2026 3:00:00 AM
